Tamoxifen or letrozole with or without bevacizumab in treating women with stage III or stage IV breast cancer

eagle-i ID

Resource Type

Properties

1. ClinicalTrials.gov url

   http://www.clinicaltrials.gov/ct2/show/NCT00601900?term=NCT00601900&rank=1

2. Intervention

   Tamoxifen

3. Intervention

   Letrozole

4. Intervention

   Bevacizumab

5. Additional Topic(s)

   Antineoplastic combined chemotherapy

6. Resource Description

   Estrogen can cause the growth of breast cancer cells. Hormone therapy using tamoxifen* or letrozole may fight breast cancer by blocking the use of estrogen by the tumor cells. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of tumor cells by blocking blood flow to the tumor. It is not yet known whether giving hormone therapy is more effective with or without bevacizumab in treating advanced breast cancer. This randomized phase III trial is studying giving tamoxifen* or letrozole together with bevacizumab to see how well it works compared with tamoxifen* or letrozole alone in treating women with stage III or stage IV breast cancer.

7. Additional Name

   Endocrine Therapy With or Without Anti-VEGF Therapy: A Randomized, Phase III Trial of Endocrine Therapy Alone or Endocrine Therapy Plus Bevacizumab (NSC 704865; IND 7921) for Women With Hormone Receptor-Positive Advanced Breast Cancer

8. Contact

   Berenberg, Jeffrey

9. PI

   Berenberg, Jeffrey

10. Topic

    breast cancer

11. Study Population

    At least 18 years old with no CNS metastases or leptomeningeal metastases, estrogen receptor-positive and/or progesterone receptor-positive disease, and meeting certainly therapy-related criteria.

12. Funded by

    Cancer Trials Support Unit

13. Phase

    Phase 3 clinical trial

14. Performed by

    Clinical Protocol & Data Management Shared Resource